Form 4: United Therapeutics CFO Executes Stock Option Plan

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-established Rule 10b5-1 plan.

Summary

• CFO James Edgemond exercised 10,000 stock options at a strike price of $135.42.
• Following the exercise, the reporting person sold 10,000 shares of common stock in multiple tranches.
• The sales occurred at weighted average prices ranging from $569.46 to $580.45 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on October 31, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent standard executive financial management.

Positives

• The transaction was executed under a pre-planned Rule 10b5-1 program, indicating the sales were not based on non-public information.
• The executive retains a significant remaining stake of 18,876 shares of common stock.

Negatives

• The transaction represents a reduction in the executive's direct equity ownership in the company.

Risks

• Future share price volatility could impact the value of remaining holdings.
• Reliance on Rule 10b5-1 plans does not eliminate market risk for the executive.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard practice for executives managing personal liquidity and tax obligations, and generally does not signal a change in corporate strategy or outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard governance practice among S&P 500 and biotech executives to ensure compliance with insider trading regulations.
• The volume of shares sold is consistent with typical executive compensation liquidation patterns.

Stakeholder Impact

• Minimal impact on shareholders as the sales were pre-scheduled and executed through a transparent regulatory mechanism.

Next Steps

• Reporting of future transactions as required by SEC Section 16(a) filings.

Key Dates

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, CFO, Stock Options, Rule 10b5-1